Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more
Excelsior Biopharma (6496) - Total Assets
Latest total assets as of June 2025: NT$1.42 Billion TWD
Based on the latest financial reports, Excelsior Biopharma (6496) holds total assets worth NT$1.42 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Excelsior Biopharma - Total Assets Trend (2017–2024)
This chart illustrates how Excelsior Biopharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Excelsior Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Excelsior Biopharma's total assets of NT$1.42 Billion consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.2% |
| Accounts Receivable | NT$182.93 Million | 11.6% |
| Inventory | NT$302.93 Million | 19.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Excelsior Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Excelsior Biopharma's current assets represent 49.0% of total assets in 2024, a decrease from 88.3% in 2017.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2024, down from 52.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
Excelsior Biopharma Competitors by Total Assets
Key competitors of Excelsior Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Excelsior Biopharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Excelsior Biopharma generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Excelsior Biopharma is currently not profitable relative to its asset base.
Excelsior Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.40 | 3.91 | 5.86 |
| Quick Ratio | 1.82 | 2.80 | 4.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$449.99 Million | NT$ 683.67 Million | NT$ 1.37 Billion |
Excelsior Biopharma - Advanced Valuation Insights
This section examines the relationship between Excelsior Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | NT$1.58 Billion |
| Market Capitalization | $13.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Excelsior Biopharma's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Excelsior Biopharma's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Excelsior Biopharma (2017–2024)
The table below shows the annual total assets of Excelsior Biopharma from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.58 Billion | +0.06% |
| 2023-12-31 | NT$1.58 Billion | -8.03% |
| 2022-12-31 | NT$1.71 Billion | -6.75% |
| 2021-12-31 | NT$1.84 Billion | -3.22% |
| 2020-12-31 | NT$1.90 Billion | +26.78% |
| 2019-12-31 | NT$1.50 Billion | -8.83% |
| 2018-12-31 | NT$1.64 Billion | -2.09% |
| 2017-12-31 | NT$1.68 Billion | -- |